Biogen Inc. $BIIB Stock Purchased by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC increased its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 776.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,271 shares of the biotechnology company’s stock after buying an additional 18,844 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Biogen were worth $4,805,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in Biogen during the 2nd quarter valued at about $3,453,878,000. Primecap Management Co. CA purchased a new stake in Biogen in the second quarter valued at about $3,274,304,000. Wellington Management Group LLP raised its stake in Biogen by 5.3% in the second quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock valued at $673,560,000 after buying an additional 155,828 shares during the last quarter. Amundi boosted its holdings in Biogen by 91.8% in the second quarter. Amundi now owns 1,516,831 shares of the biotechnology company’s stock worth $327,727,000 after acquiring an additional 726,004 shares in the last quarter. Finally, Legal & General Group Plc acquired a new stake in Biogen in the second quarter worth about $322,640,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Biogen Price Performance

NASDAQ BIIB opened at $243.10 on Wednesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26. The stock’s fifty day moving average price is $221.28 and its 200 day moving average price is $204.74. Biogen Inc. has a 1 year low of $138.00 and a 1 year high of $244.65. The company has a market cap of $35.92 billion, a price-to-earnings ratio of 43.03, a PEG ratio of 2.60 and a beta of 0.09.

Biogen (NASDAQ:BIIB) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The company had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.46 billion. During the same quarter last year, the business posted $5.47 EPS. The firm’s quarterly revenue was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities research analysts forecast that Biogen Inc. will post 12.31 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on BIIB shares. Wall Street Zen lowered Biogen from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Canaccord Genuity Group increased their price objective on shares of Biogen from $245.00 to $248.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Seaport Research Partners raised shares of Biogen to an “outperform” rating in a research report on Monday, October 12th. Oppenheimer reiterated an “outperform” rating and issued a $300.00 target price on shares of Biogen in a research note on Wednesday, July 29th. Finally, Royal Bank Of Canada lowered their target price on shares of Biogen from $260.00 to $256.00 and set an “outperform” rating for the company in a research note on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $239.96.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen announced that 76-week EMPAVELI® (pegcetacoplan) data to be presented at ASN Kidney Week showed sustained proteinuria reduction, continued stabilization of kidney function and a consistent long-term safety profile in patients with C3G and primary IC-MPGN. The data supports the commercial potential of EMPAVELI following its expanded FDA approval. Biogen nephrology data announcement
• Positive Sentiment: The company is highlighting a broader nephrology strategy, including investigational felzartamab programs in antibody-mediated rejection, IgA nephropathy and membranous nephropathy. Investors may view these programs, along with the Apellis acquisition, as potential sources of growth and earnings accretion beginning in 2027. Biogen kidney-disease data and pipeline analysis
• Positive Sentiment: Wells Fargo raised its Biogen price target from $250 to $310 and maintained an “overweight” rating, reinforcing bullish sentiment toward the company’s pipeline and longer-term growth outlook.
• Positive Sentiment: Recent analyst coverage remains constructive, with Needham, Evercore ISI and Guggenheim issuing buy or outperform ratings. Institutional ownership was also mixed but leaned positive, with more investors adding shares than reducing positions in the latest reported quarter.
• Neutral Sentiment: Investors are likely positioning ahead of Biogen’s third-quarter 2026 earnings report and webcast scheduled for October 28, which could provide updates on EMPAVELI sales, the Apellis integration and full-year expectations.
• Negative Sentiment: Valuation indicators provide a counterpoint: GuruFocus’ estimated GF Value of $202.16 is below the referenced market price, while the median analyst price target of $223.50 is also lower. EMPAVELI carries a boxed warning for serious infections and requires a REMS program, potentially limiting adoption.
• Negative Sentiment: Biogen insider activity has been unfavorable, with two reported insider sales and no purchases during the past six months. Felzartamab also remains investigational, so its projected contribution depends on future clinical and regulatory success.

Biogen Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.